Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

Life Science Sweden´s international issue is on its way

A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.

Hög biologisk ålder kopplas till ökad risk för demens och stroke

Människor åldras i olika takt, som bekant. Nu indikerar en studie vid Karolinska institutet att personer med högre biologisk ålder än deras faktiska ålder löper...

Rapid developments in AI – “All stakeholders are struggling to understand it”

Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, ke...

Swedish and Danish Life Science – are there still untapped synergies?

With the increasing developments in life sciences over the past decade and strong support for the sector’s strategic importance from both the Sweden and Danish ...

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...

Bud på Biotage – värderas till över 11 miljarder

Uppsalabaserade Biotage meddelade på tisdagen att det amerikanska investmentbolaget KKR har lagt ett kontantbud på biotechbolaget.

Major advances in IVF labs in the last few decades

Since the introduction of in vitro fertilisation several decades ago, many developments have been made in the field, and the main part of that development has t...

Amrop Malmö AB

Anna Törner: Vem betalar för Rebecca Doe – och alla oss andra?

Det lätt att vänja sig vid tanken att vård och läkemedel är gratis, när det egentligen handlar om hur och vem som betalar. Det skriver Anna Törner i en krönika.

Giulia Gaudenzi: ”Key lessons from global health research”

The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.

The route to vaccines for everyone: “We did not just sit around and wait”

The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a propos...

Drug development creates new challenges for regulators

Stayble får europeiskt patent för engångsbehandling mot diskbråck

Stayble Therapeutics är på väg att beviljas ett europeiskt patent för sin behandling av diskbråck.

Try arivis for free

30-day free trial offers a number of benefits.

HAB Nicolai Johannsen

New Horizons in Biologics & Bioprocessing: Stockholm

Bioarctic fälls för vd-uttalanden till journalist – efter anmälan från konkurrent

I ett vägledande utslag fälls alzheimerbolaget Bioarctic för uttalanden som bolagets vd gjorde till en ekonomijournalist i somras.

Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Scien...

The new Astra Zeneca CEO: “An incredibly exciting phase”

Almost 27 years have passed since Per Alfredsson from Södertälje stepped into Astra Zeneca as a newly hired engineer. After countless different roles, including...

“Photon counting in computed tomography is the holy grail”

Erik Fredenberg, a researcher in physics at KTH and GE, is working to implement photon-counting CT in clinics. To shorten lead times and reduce the radiation do...

Björn Arvidsson: ”Framtiden byggs inte av solospelare”

Björn Arvidsson skriver om vikten av samarbete och tillit mellan hälso- och sjukvården och life science-branschen.

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.